Tevimbra (Tislelizumab-jsgr)
What is Tevimbra?
Tevimbra is an immunotherapy infusion drug used to treat certain advanced or metastatic cancers, including esophageal squamous cell carcinoma (ESCC) and gastric/gastroesophageal junction adenocarcinoma. It works by blocking the PD-1 protein on immune cells, helping your body attack cancer cells more effectively [1][5][7].
How is it given?
Administered via IV infusion every 3 weeks [1][2][5].
First dose takes 60 minutes; later doses may be shortened to 30 minutes if tolerated [1][5].
Before starting Tevimbra, tell your doctor if you:
Have autoimmune diseases (e.g., lupus, Crohn’s) or a history of organ transplants [1][2].
Are pregnant/planning pregnancy (requires contraception during and for 4 months post-treatment) [1][5].
Are breastfeeding (avoid during and for 4 months after treatment) [1][5].
Possible side effects:
Common reactions include fatigue, rash, or digestive issues. Serious but rare side effects may involve:
Lung problems (trouble breathing, cough).
Liver issues (yellowing skin, dark urine).
Hormonal gland changes (unusual headaches, weight fluctuations) [1][2][7].
During treatment:
Keep all medical appointments for blood tests and monitoring.
Inform healthcare providers you’re on Tevimbra before any procedures or new medications [2][5].
Support resources:
The myBeOne Support program offers nurse advocates to help with treatment access, education, and caregiver support[6]. Call 1-833-234-4363 (M–F, 8 AM–8 PM ET).
Always consult your care team with questions or concerns about your treatment plan.
Citations:
[1] https://www.drugs.com/tevimbra.html
[2] https://www.medsafe.govt.nz/consumers/cmi/t/TevimbraInj.pdf
[3] https://www.tevimbrahcp.com/resources/
[4] https://www.hca.wa.gov/assets/pebb/sebb-regence-ump-preauthreqs-medication-covered-under-medical.pdf
[5] https://www.drugs.com/pro/tevimbra.html
[6] https://www.tevimbra.com/escc/resources/
[7] https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761417s000lbl.pdf
[8] https://quizlet.com/775218490/drug-information-resources-quiz-part-11-flash-cards/
[9] https://www.ema.europa.eu/en/medicines/human/EPAR/tevimbra
[10] https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761232Orig1s000lbl.pdf
Share this post